OxyContin, prescription opioid abuse and economic medicalization

Geoffrey Poitras

Post-Print from HAL

Abstract: This paper examines the relevance of OxyContin diversion and abuse to the economic medicalization of substance abuse and addiction. Given that medicalization is the general social process of nonmedical problems being transformed into medical problems, economic medicalization occurs where the motivation for the transformation is commercial profitability or, in a corporate context, achieving the objective of shareholder wealth maximization. After considering potential conflicts between medical ethics and business ethics, practical aspects of economic medicalization are detailed by considering the methods used to market OxyContin by Purdue Pharma. Illegal practices are identified and contrasted with legal practices that facilitated economic medicalization. Implications of medicalization research for designing public heath solutions to the epidemic of prescription opioid abuse are discussed.

Keywords: medicalization; OxyContin; prescription drug abuse; medical ethics (search for similar items in EconPapers)
Date: 2012-11
Note: View the original document on HAL open archive server: https://hal.science/hal-03680382
References: View complete reference list from CitEc
Citations:

Published in Medicolegal and Bioethics, 2012, pp.31. ⟨10.2147/MB.S32040⟩

Downloads: (external link)
https://hal.science/hal-03680382/document (application/pdf)

Related works:
Working Paper: OxyContin, prescription opioid abuse and economic medicalization (2012)
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-03680382

DOI: 10.2147/MB.S32040

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().